Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced that Carole
Huntsman has been appointed Chief Commercial Officer.
Ms. Huntsman was most recently Senior Vice President, Head of
Specialty Care North America and U.S. Country Lead at Sanofi, where
she directed 2,600 team members across multiple product launches in
immunology, neurology, oncology, rare diseases, and rare blood
disorders. This included executing the launch of Dupixent, a
first-in-class therapy which has grown into an industry-leading
medicine. In 2022, Ms. Huntsman’s business unit was responsible for
over $10 billion in annual net sales.
Bill Sibold, Chief Executive Officer of Madrigal, stated,
“Carole Huntsman’s leadership skills and experience are a perfect
fit for Madrigal as we prepare for a first-to-market launch of
resmetirom in the U.S. She has an extensive track record of
specialty launch success and excels in building and leading
high-performing teams that deliver innovative new therapies to
patients with serious diseases. I’m thrilled to welcome Carole to
Madrigal and look forward to working with her as we continue to
build a world-class commercial organization.”
From 2012 until joining Madrigal, Ms. Huntsman held positions of
increasing responsibility at Sanofi, including Head of Multiple
Sclerosis, Oncology & Immunology Specialty Care North America,
Global Multiple Sclerosis Lead, Sanofi Genzyme, and Vice President,
Business Unit Head, Multiple Sclerosis, North America Sanofi
Genzyme. Prior to joining Sanofi, she served as Senior Vice
President, U.S. Neurology & Rheumatology at EMD Serono, Inc.
and Vice President, Marketing U.S. Neurology at Serono, Inc. Prior
to joining the biopharmaceutical industry, she served in the U.S.
Army. Ms. Huntsman holds a B.A. Degree in History from Boston
College and an M.B.A. from The Carroll School, Boston College.
Ms. Huntsman stated, “I’m very excited to join Madrigal at this
pivotal time and look forward to working closely with the
healthcare community and our internal teams to prepare for and
execute the launch of our first-in-class, transformational therapy
for patients with NASH.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a liver-directed THR-β agonist oral therapy that is
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Forward Looking Statements
This communication includes “forward-looking statements” made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, that are based on Madrigal’s beliefs
and assumptions and on information currently available to it, but
are subject to factors beyond its control. Forward-looking
statements reflect management’s current knowledge, assumptions,
judgment and expectations regarding future performance or events.
Forward-looking statements include: all statements that are not
historical facts; statements referenced by forward-looking
statement identifiers, including the examples in the paragraph
below; resmetirom’s potential to be the first specialty therapy for
NASH patients with significant liver fibrosis; statements
concerning potential accelerated approval; and statements or
references concerning - the potential efficacy and safety of
resmetirom for noncirrhotic NASH patients and cirrhotic NASH
patients, possible or assumed future results of operations and
expenses, business strategies and plans (including ex-US.
Launch/partnering plans), research and development activities, and
the timing and results associated with the future development of
resmetirom, the timing and completion of projected future clinical
milestone events, including enrollment, additional studies,
top-line data and open label projections, plans, objectives, timing
and support for making for making a Subpart H (Accelerated Approval
of New Drugs for Serious or Life-Threatening Illnesses) submission
to FDA, projections or objectives for obtaining accelerated or full
approval for resmetirom, Madrigal’s primary and key secondary study
endpoints for resmetirom and the potential for achieving such
endpoints and projections, demonstrating clinical benefit to
support accelerated approval, the potential to support an
additional indication for resmetirom in patients with
well-compensated NASH cirrhosis, optimal dosing levels for
resmetirom and projections regarding potential NASH or NAFLD and
potential patient benefits with resmetirom, including future NASH
resolution, safety, fibrosis treatment, cardiovascular effects,
lipid treatment, and/or biomarker effects with resmetirom.
Forward-looking statements can be identified by terms such as
“accelerate,” “achieve,” “allow,” “anticipates,” “appear,” “be,”
“believes,” “can,” “confidence,” “continue,” “could,”
“demonstrates,” ”design,” “estimates,” “expectation,” “expects,”
“forecasts,” “future,” “goal,” “help,” “hopeful,” “inform,”
inform,” “intended,” “intends,” “may,” “might,” “on track,”
“planned,” “planning,” “plans,” “positions,” “potential,” “powers,”
“predicts,” ”predictive,” “projects,” “seeks,” “should,” “will,”
“will achieve,” “will be,” “would” or similar expressions and the
negatives of those terms.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to: the assumptions
underlying the forward-looking statements; risks of obtaining and
maintaining regulatory approvals, including, but not limited to,
potential regulatory delays or rejections; risks associated with
meeting the objectives of Madrigal’s clinical studies, including,
but not limited to Madrigal’s ability to achieve enrollment
objectives concerning patient numbers (including an adequate safety
database), outcomes objectives and/or timing objectives for
Madrigal’s studies; any delays or failures in enrollment, and the
occurrence of adverse safety events; risks related to the effects
of resmetirom’s mechanism of action; the achievement of enrollment
objectives concerning patient number, safety database and/or timing
for Madrigal’s studies; enrollment and trial conclusion
uncertainties; market demand for and acceptance of our products;
the potential inability to raise sufficient capital to fund ongoing
operations as currently planned or to obtain financings on terms
similar to those arranged in the past; the ability to service
indebtedness and otherwise comply with debt covenants; outcomes or
trends from competitive studies; future topline data timing or
results; our ability to prevent and/or mitigate cyber attacks,
unauthorized exfiltration of data or other security incidents; the
risks of achieving potential benefits in studies that includes
substantially more patients, and patients with different disease
states, than prior studies; the timing and outcomes of clinical
studies of resmetirom; and the uncertainties inherent in clinical
testing. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Madrigal
undertakes no obligation to update any forward-looking statements
to reflect new information, events, or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events. Please refer to Madrigal’s submissions filed with the U.S.
Securities and Exchange Commission, or SEC, for more detailed
information regarding these risks and uncertainties and other
factors that may cause actual results to differ materially from
those expressed or implied. Madrigal specifically discusses these
risks and uncertainties in greater detail in the sections appearing
in Part I, Item 1A of its Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the SEC on February 23, 2023,
as amended by our Form 10-K/A filed with the SEC on March 3, 2023,
and Part II, Item 1A of its Quarterly Reports on Form 10-Q for the
quarters ended June 30, 2023 and September 30, 2023, and as updated
from time to time by Madrigal’s other filings with the SEC.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024